Oxford Biomedica PLC ORD 50P
Oxford Biomedica PLC ORD 50P/ GB00BDFBVT43 /
OXB
|
10/10/2024 17:18:18
|
Diferencia
+0.8000
|
Volumen |
Bid17:56:00 |
Ask17:36:34 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
385.8000GBX
|
+0.21%
|
19,586
Volumen de negocios(GBP): 75,018.5367 |
292.0000Volumen de oferta: 1,697 |
390.0000Tamaño/ Volumen/ Formato de Ask: 1,228 |
308.02 millonesGBP |
- |
- |
Descripción de negocio
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
Consejo de gestión & Consejo de supervisión
| CEO |
| John Dawson |
| Consejo de gestión |
| Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page |
| Consejo de supervisión |
| Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter |
Datos de la empresa
| Nombre: |
Oxford BioMedica plc |
| Dirección: |
Windrush Court, Transport Way,UK-Oxford OX4 6LT |
| Teléfono: |
+44-1865-783-000 |
| Fax: |
+44-1865-783-001 |
| E-mail: |
enquiries@oxfordbiom...a.co.uk
enquiries@oxfordbiomedica.co.uk
|
| Internet: |
https://www.oxb.com/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
50.20% |
| Fecha de OPI: |
- |
Accionistas mayoritarios
| Freefloat |
|
50.20% |
| Vulpes Investment Management |
|
11.90% |
| Novo Holdings |
|
10.00% |
| M&G Investments |
|
8.70% |
| Liontrust Asset Management |
|
5.00% |
| Nine Ten Capital |
|
3.80% |
| Hargreaves Lansdown Asset Management |
|
3.70% |
| Mr. S M H Shah |
|
3.50% |
| Artisan Partners |
|
3.20% |
